NGM Bio Names Castlight’s Nolan Mangini as Its Chief Financial Officer

NGM Biopharmaceuticals (NASDAQ: [[ticker:NGM]]) added Siobhan Nolan Mangini to its C-suite as chief financial officer. Nolan Mangini, formerly president and CFO of Castlight Health (NYSE: [[ticker:CSLT]]), starts the new role at South San Francisco-based NGM on July 13. Prior to Castlight, Nolan Mangini’s experience includes time as a management consultant at Bain & Company and a financial associate at the Henry J. Kaiser Family Foundation.

NGM’s lead drug candidate, a once-daily injection called aldafermin, is an engineered variant of the human hormone fibroblast growth factor 19 that is currently in mid-stage testing for the treatment of nonalcoholic fatty liver disease (NASH).

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.